Drug Trial Radar · NCT07564596
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Climb Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts.
Conditions
- Systemic Lupus Erthematosus
Interventions
BudoprutugDrug
Single IV dose of study product on Day 1 and Day 15
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to week 28
- Incidence of Clinical Laboratory AbnormalitiesTime frame: Up to week 28
- Incidence of dose-limiting toxicities (DLTs)Time frame: up to 28 weeks
- Change from Baseline in Systolic Blood PressureTime frame: Up to week 28
- Change from Baseline in Diastolic Blood PressureTime frame: up to 28 weeks
- Change from Baseline in Heart RateTime frame: up to 28 weeks
- Change from Baseline in Respiratory RateTime frame: up to 28 weeks
- Change from Baseline in Body TemperatureTime frame: up to 28 weeks
- Change from Baseline in PR IntervalTime frame: up to 28 weeks
- Change from Baseline in QRS DurationTime frame: up to 28 weeks
- Change from Baseline in QT IntervalTime frame: up to 28 weeks
- Change from Baseline in QTc IntervalTime frame: up to 28 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Baoji Central Hospital
Baoji, China · Recruiting
Peking University People's Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Not yet recruiting
Xiangya Second Hospital of Central South University
Changsha, China · Not yet recruiting
The First Affiliated Hospital of the University of Science
Hefei, China · Not yet recruiting
The First Affiliated Hospital of Nanchang
Nanchang, China · Not yet recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, China · Not yet recruiting
Shanxi Bethune Hospital
Taiyuan, China · Recruiting
Zaozhuang Municipal Hospital
Zaozhuang, China · Not yet recruiting
Mianyang Central Hospital
Mianyang, Sichuan, China · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.